Select Publications

Conference Abstracts

Alvarez H; Mocroft A; Ryom L; Neesgaard B; Edwards S; Svedhem-Johansson V; Gunthard H; Zangerle R; Smith C; Castagna A; Monforte AD; Wit F; Stecher M; Lehman C; Mussini C; Fontas E; Gonzalez E; Wasmuth J-C; Sonnerborg A; De Wit S; Chkhartishvili N; Stephan C; Petoumenos K; Jaschinski N; Vannappagari V; Rooney J; Young L; Anne AV; Greenberg L; Martin-Iguacel R; Poveda E; Llibre J, 2022, 'Initial plasma HIV-1 RNA and CD4+T-cell count are determinants of virological outcomes with initial integrase inhibitor-based regimens: a prospective multinational RESPOND cohort consortium', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 25, pp. 199 - 200,

Jaschinski N; Neesgaard B; Wit F; van der Valk M; Gunthard H; Stockle M; Wallner E; Kowalska J; Ridolfo A; Nowak P; Castagna A; Monforte AD; Chkhartishvili N; Petoumenos K; Hoy J; Garges H; Rooney J; Young L; Hosein S; Lundgren J; Peters L; Mocroft A; Ryom L, 2022, 'Use of preventive measures for cardiovascular disease in people living with HIV', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 25, pp. 3 - 4,

Matthews G; Bhagani S; Van der Valk M; Rockstroh JK; Kim AY; Thurnheer C; Feld JJ; Bruneau J; Gane EJ; Hellard M; Grebely J; Applegate T; Marks P; Martinello M; Petoumenos K; Dore G, 2019, 'SHORT COURSE DURATION SOFOSBUVIR/VELPATASVIR IS INFERIOR TO STANDARD DURATION THERAPY IN THE TREATMENT OF RECENTLY ACQUIRED HCV INFECTION: RESULTS FROM REACT STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 1487A - 1488A, presented at 70th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019,

Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthew G, 2019, 'Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E734 - E734, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019,

Martinello M; Cerrone M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Schoolmeesters A; Grebely J; Nelson M; Matthews GV, 2018, 'TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection', in HIV MEDICINE, WILEY, Vol. 19, pp. S151 - S152,

Martinello M; Bhagani S; Gane EJ; Orkin C; Cooke G; Kulasegaram R; Shaw D; Hellard M; Tu E; Filep E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews G, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017,

Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,

Back to profile page